Febuxostat tablet with improved dissolution rate

Abstract

The invention discloses a Febuxostat tablet and a preparation method thereof. The Febuxostat tablet comprises a tablet core and a coating. The tablet core comprises the following components in weight percentage: 5-30 percent of Febuxostat, 15-60 percent of filler, 1-20 percent of disintegrating agent, 0.1-5 percent of surface active agent, 0.1-8 percent of lubricant and a right amount of adhesive. According to the Febuxostat tablet, trough adopting the powerful disintegrating agent within a reasonable proportional region, and meanwhile, through jointly using the surface active agent, the poorly water-soluble drug Febuxostat dissolves out, and further, the dissolvability of the Febuxostat is increased, and the bioavailability of the Febuxostat is improved. Moreover, the Febuxostat tablet is simple in preparation method, controllable in quality and high in stability.

Description

technical field

[0001] The invention relates to the field of medicine, in particular to a febuxostat tablet. Background technique

[0002] The occurrence of gout is due to the excessive production of uric acid in the body and the decline in the ability of the kidneys to clear it. The accumulation of uric acid in the body leads to the deposition of urate crystals in the joints and various organs. Uric acid has no physiological function in the human body. Under normal circumstances, 2 / 3 of the uric acid produced in the body is excreted by the kidneys, and the remaining 1 / 3 is excreted from the intestines. Uric acid in the body is constantly produced and excreted, so it maintains a certain concentration in the blood. The uric acid contained in each liter of blood of normal people is less than 0.42mmol for men and no more than 0.357mmol for women. In the process of synthesis and decomposition of purine, various enzymes are involved. Due to the congenital abnormality of the enz...

Images